186 related articles for article (PubMed ID: 33860045)
1. Human Schlafen 5 Inhibits Proliferation and Promotes Apoptosis in Lung Adenocarcinoma via the PTEN/PI3K/AKT/mTOR Pathway.
Gu X; Zhou L; Chen L; Pan H; Zhao R; Guang W; Wan G; Zhang P; Liu D; Deng LL; Zhao W; Lu C
Biomed Res Int; 2021; 2021():6628682. PubMed ID: 33860045
[TBL] [Abstract][Full Text] [Related]
2. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
[TBL] [Abstract][Full Text] [Related]
3. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
4. Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
Zhang S; Ma Y; Hu X; Zheng Y; Chen X
J Cell Mol Med; 2019 Feb; 23(2):1333-1342. PubMed ID: 30461193
[TBL] [Abstract][Full Text] [Related]
5.
Lu XX; Cao LY; Chen X; Xiao J; Zou Y; Chen Q
Biomed Res Int; 2016; 2016():2476842. PubMed ID: 27822469
[No Abstract] [Full Text] [Related]
6. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA TTN-AS1 promotes the progression of lung adenocarcinoma by regulating PTEN/PI3K/AKT signaling pathway.
Luo J; Liu Z
Biochem Biophys Res Commun; 2019 Jun; 514(1):140-147. PubMed ID: 31027732
[TBL] [Abstract][Full Text] [Related]
8. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer.
Cai J; Fang L; Huang Y; Li R; Yuan J; Yang Y; Zhu X; Chen B; Wu J; Li M
Cancer Res; 2013 Sep; 73(17):5402-15. PubMed ID: 23856247
[TBL] [Abstract][Full Text] [Related]
9. METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.
Bi X; Lv X; Liu D; Guo H; Yao G; Wang L; Liang X; Yang Y
Cancer Gene Ther; 2021 Apr; 28(3-4):335-349. PubMed ID: 32939058
[TBL] [Abstract][Full Text] [Related]
10. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
11. MiR-181a reduces radiosensitivity of non-small-cell lung cancer via inhibiting PTEN.
Chen Y; Liao W; Yuan A; Xu H; Yuan R; Cao J
Panminerva Med; 2022 Sep; 64(3):374-383. PubMed ID: 32506887
[TBL] [Abstract][Full Text] [Related]
12. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Neural Precursor Cell Expressed Developmentally Downregulated 4-1 is Associated with Poor Prognosis and Chemoresistance in Lung Adenocarcinoma.
Song YH; Zhang CQ; Chen FF; Lin XY
Chin Med J (Engl); 2018 Jan; 131(1):16-24. PubMed ID: 29271375
[TBL] [Abstract][Full Text] [Related]
14. Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.
Lee KY; Shueng PW; Chou CM; Lin BX; Lin MH; Kuo DY; Tsai IL; Wu SM; Lin CW
Cancer Sci; 2020 May; 111(5):1652-1662. PubMed ID: 32133706
[TBL] [Abstract][Full Text] [Related]
15. SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression.
Xiong L; Tan B; Lei X; Zhang B; Li W; Liu D; Xia T
IUBMB Life; 2021 Sep; 73(9):1092-1102. PubMed ID: 34033225
[TBL] [Abstract][Full Text] [Related]
16. Kaempferol inhibits proliferation, migration, and invasion of liver cancer HepG2 cells by down-regulation of microRNA-21.
Zhu G; Liu X; Li H; Yan Y; Hong X; Lin Z
Int J Immunopathol Pharmacol; 2018; 32():2058738418814341. PubMed ID: 30477356
[TBL] [Abstract][Full Text] [Related]
17. BMI1 promotes cardiac fibrosis in ischemia-induced heart failure via the PTEN-PI3K/Akt-mTOR signaling pathway.
Yang W; Wu Z; Yang K; Han Y; Chen Y; Zhao W; Huang F; Jin Y; Jin W
Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H61-H69. PubMed ID: 30359076
[TBL] [Abstract][Full Text] [Related]
18. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
19. Cancer/testis antigen LDHC promotes proliferation and metastasis by activating the PI3K/Akt/GSK-3β-signaling pathway and the in lung adenocarcinoma.
Chen L; Wu Q; Xu X; Yang C; You J; Chen F; Zeng Y
Exp Cell Res; 2021 Jan; 398(2):112414. PubMed ID: 33301764
[TBL] [Abstract][Full Text] [Related]
20. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM
Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
